keyword
MENU ▼
Read by QxMD icon Read
search

Meningococcal Serogroup B Vaccine

keyword
https://www.readbyqxmd.com/read/28196734/bactericidal-activity-of-sera-from-adolescents-vaccinated-with-bivalent-rlp2086-against-meningococcal-serogroup-b-outbreak-strains-from-france
#1
Muhamed-Kheir Taha, Julio Cesar Hawkins, Paul Liberator, Ala-Eddine Deghmane, Lubomira Andrew, Li Hao, Thomas R Jones, Lisa K McNeil, Robert E O'Neill, John L Perez, Kathrin U Jansen, Annaliesa S Anderson
OBJECTIVES: Bivalent rLP2086 (Trumenba®; MenB-FHbp), composed of two factor H binding proteins (FHbps), is a vaccine approved in the United States for prevention of Neisseria meningitidis serogroup B (MnB) invasive meningococcal disease (IMD). Bactericidal activity of sera from subjects vaccinated with bivalent rLP2086 was assessed against MnB isolates from recent disease outbreaks in France. METHODS: MnB isolates from IMD cases were characterized by whole genome sequencing and FHbp expression was assessed using a flow cytometry-based assay...
February 10, 2017: Vaccine
https://www.readbyqxmd.com/read/28192234/meningococcal-carriage-in-dutch-adolescents-and-young-adults-a-cross-sectional-and-longitudinal-cohort-study
#2
Mariëtte B van Ravenhorst, Merijn W Bijlsma, Marlies A van Houten, Veerle M D Struben, Annaliesa S Anderson, Joseph Eiden, Hao Li, Kathrin U Jansen, Hal Jones, Nicholas Kitchin, Louise Pedneault, Elisabeth A M Sanders, Arie van der Ende
OBJECTIVES: Current information on rates and dynamics of meningococcal carriage is essential for public health policy. This study aimed to determine meningococcal carriage prevalence, its risk factors and duration in the Netherlands, where meningococcal C vaccine coverage is >90%. Several methods to identify serogroups of meningococcal carriage isolates among adolescent and young adults were compared. METHODS: Oropharyngeal swabs from 1715 subjects 13-23 years of age were collected in 2013-2014; 300 were prospectively followed over 8 months...
February 10, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28167517/the-need-to-optimize-adolescent-immunization
#3
Henry H Bernstein, Joseph A Bocchini
The adolescent period heralds the pediatric patient's transition into adulthood. It is a time of dynamic development during which effective preventive care measures can promote safe behaviors and the development of lifelong health habits. One of the foundations of preventive adolescent health care is timely vaccination, and every visit can be viewed as an opportunity to update and complete an adolescent's immunizations.In the past decade, the adolescent immunization schedule has expanded to include 2 doses of quadrivalent meningococcal conjugate vaccine, 1 dose of tetanus, diphtheria, acellular pertussis, absorbed vaccine, 2 or 3 doses of human papillomavirus vaccine, depending on the child's age, and an annual influenza vaccine...
February 6, 2017: Pediatrics
https://www.readbyqxmd.com/read/28158417/meningococcal-carriage-evaluation-in-response-to-a-serogroup-b-meningococcal-disease-outbreak-and-mass-vaccination-campaign-at-a-college-rhode-island-2015-2016
#4
Heidi M Soeters, Melissa Whaley, Nicole Alexander-Scott, Koren V Kanadanian, Jessica R MacNeil, Stacey W Martin, Lucy A McNamara, Kenneth Sicard, Cynthia Vanner, Jeni Vuong, Xin Wang, Utpala Bandy, Manisha Patel
No abstract text is available yet for this article.
February 4, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28146198/-meningococcal-invasive-disease-caused-by-serogroup-b-in-two-chilean-children-vaccinated-against-acwy-serogroups
#5
Rodolfo Villena, Josefa González
Invasive meningococcal disease (IMD) by serogroup W has become predominant in Chile since 2012, prompting vaccination with conjugate ACWY. We reported two pediatric cases in patients already vaccinated, which evolved with IMD by serogroup B. This should remind us to keep the alertness with this pathology, despite the current vaccination system in Chile, emphasizing in improve our epidemiological case definition and its diagnosis.
December 2016: Revista Chilena de Infectología: órgano Oficial de la Sociedad Chilena de Infectología
https://www.readbyqxmd.com/read/28140784/the-prevalence-serogroup-distribution-and-risk-factors-of-meningococcal-carriage-in-adolescents-and-young-adults-in-turkey
#6
Rahmi Tuna Tekin, Ener Cagri Dinleyici, Mehmet Ceyhan, Adem Karbuz, Nuran Salman, Murat Sutçu, Zafer Kurugol, Yasemin Balliel, Melda Celik, Mustafa Hacimustafaoglu, Necdet Kuyucu, Meda Kondolot, Gülnar Sensoy, Ozge Metin, Soner Sertan Kara, Meltem Dinleyici, Omer Kılıç, Cihangul Bayhan, Venhar Gurbuz, Emre Aycan, Aygun Memedova, Arzu Karli, Gulçin Bozlu, Solmaz Celebi
The serogroup epidemiology of invasive meningococcal disease (IMD), which varies considerably by geographic region and immunization schedule, changes continuously. Meningococcal carriage data are crucial for assessing IMD epidemiology and designing f potential vaccination strategies. Meningococcal seroepidemiology in Turkey differs from that in other countries: serogroups W and B are the predominant strains for IMD during childhood, whereas no serogroup C cases were identified over the last 10 years and no adolescent peak for IMD was found...
January 31, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28124080/serologic-response-to-meningococcal-vaccination-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh-chronically-treated-with-the-terminal-complement-inhibitor-eculizumab
#7
Ferras Alashkar, Colin Vance, Dörte Herich-Terhürne, Nicole Preising, Ulrich Dührsen, Alexander Röth
Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on eculizumab are susceptible to Neisseria meningitidis infections. The two mainstays to reduce the risk of infection are vaccination and antibiotic prophylaxis. In this retrospective study, serologic response was analyzed after vaccination with a meningococcal vaccine in 23 PNH patients (median age 36 years; range 25 - 88 years; 15 males, 8 females) by measuring serum bactericidal assay (SBA) using rabbit complement (rSBA) titers against meningococcal serogroups A, C, W, and Y...
January 26, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28121236/rapid-response-to-a-college-outbreak-of-meningococcal-serogroup-b-disease-nation-s-first-widespread-use-of-bivalent-rlp2086-vaccine
#8
Theresa M Fiorito, Suzanne Bornschein, Alysia Mihalakos, Catherine M Kelleher, Nicole Alexander-Scott, Koren V Kanadanian, Patricia Raymond, Kenneth Sicard, Penelope H Dennehy
OBJECTIVE: To outline the reasoning behind use of bivalent rLP2086 in a Rhode Island college meningococcal B (MenB) disease outbreak, highlighting the timeline from outbreak declaration to vaccination clinic, emphasizing that these two time points are < 3 days apart. PARTICIPANTS: Staff, faculty, and students at College X eligible for vaccination. METHODS: An outbreak response was initiated, advantages/disadvantages of available MenB vaccines were discussed, and a vaccination clinic was coordinated...
January 25, 2017: Journal of American College Health: J of ACH
https://www.readbyqxmd.com/read/27960595/meningococcal-serogroup-b-vaccines-estimating-breadth-of-coverage
#9
Robert G K Donald, Julio Cesar Hawkins, Li Hao, Paul Liberator, Thomas R Jones, Shannon L Harris, John L Perez, Joseph J Eiden, Kathrin U Jansen, Annaliesa S Anderson
Neisseria meningitidis serogroup B (MenB) is an important cause of invasive meningococcal disease. The development of safe and effective vaccines with activity across the diversity of MenB strains has been challenging. While capsular polysaccharide conjugate vaccines have been highly successful in the prevention of disease due to meningococcal serogroups A, C, W, and Y, this approach has not been possible for MenB owing to the poor immunogenicity of the MenB capsular polysaccharide. Vaccines based on outer membrane vesicles have been successful in the prevention of invasive MenB disease caused by the single epidemic strain from which they were derived, but they do not confer broad protection against diverse MenB strains...
December 14, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27939054/concomitant-administration-of-a-fully-liquid-ready-to-use-dtap-ipv-hb-prp-t-hexavalent-vaccine-with-a-meningococcal-serogroup-c-conjugate-vaccine-in-infants
#10
Timo Vesikari, Ray Borrow, Xavier Da Costa, Patrick Richard, Cécile Eymin, Florence Boisnard, Stephen Lockhart
DTaP-IPV-HB-PRP-T or hexavalent vaccines are indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). The present study evaluates the safety and immunogenicity of a ready-to-use hexavalent vaccine when co-administered with a meningococcal serogroup C conjugate (MenC) vaccine in infants. This was a phase III, open-label, randomised, multicentre study conducted in Finland...
January 11, 2017: Vaccine
https://www.readbyqxmd.com/read/27936105/serogroup-and-clonal-characterization-of-czech-invasive-neisseria-meningitidis-strains-isolated-from-1971-to-2015
#11
Zuzana Jandova, Martin Musilek, Zuzana Vackova, Jana Kozakova, Pavla Krizova
BACKGROUND: This study presents antigenic and genetic characteristics of Neisseria meningitidis strains recovered from invasive meningococcal disease (IMD) in the Czech Republic in 1971-2015. MATERIAL AND METHODS: A total of 1970 isolates from IMD, referred to the National Reference Laboratory for Meningococcal Infections in 1971-2015, were studied. All isolates were identified and characterized by conventional biochemical and serological tests. Most isolates (82...
2016: PloS One
https://www.readbyqxmd.com/read/27912986/a-phase-iii-observer-blind-randomized-controlled-study-to-evaluate-the-immune-response-and-the-correlation-with-nasopharyngeal-carriage-after-immunization-of-university-students-with-a-quadrivalent-meningococcal-acwy-glycoconjugate-or-serogroup-b-meningococcal
#12
Robert C Read, Peter Dull, Xilian Bai, Kate Nolan, Jamie Findlow, Rohit Bazaz, Annett Kleinschmidt, Maggie McCarthy, Huajun Wang, Daniela Toneatto, Ray Borrow
BACKGROUND: University students have high rates of pharyngeal carriage of Neisseria meningitidis. Interruption of carriage acquisition is an important mechanism of vaccines for inducing herd protection. 4CMenB and MenACWY-CRM vaccines have been shown to be immunogenic against meningococcal serogroups B and ACWY respectively in younger age groups, and also to elicit a modest impact on meningococcal carriage in vaccinated students. However, vaccine responses in university students and the impact of serum bactericidal antibody (SBA) titers on meningococcal carriage are undetermined...
January 11, 2017: Vaccine
https://www.readbyqxmd.com/read/27884478/vaccine-provision-delivering-sustained-widespread-use
#13
Scott Preiss, Nathalie Garçon, Anthony L Cunningham, Richard Strugnell, Leonard R Friedland
The administration of a vaccine to a recipient is the final step in a development and production process that may have begun several decades earlier. Here we describe the scale and complexity of the processes that brings a candidate vaccine through clinical development to the recipient. These challenges include ensuring vaccine quality (between 100 and 500 different Quality Control tests are performed during production to continually assess safety, potency and purity); making decisions about optimal vaccine presentation (pre-filled syringes versus multi-dose vials) that affect capacity and supply; and the importance of maintaining the vaccine cold chain (most vaccines have stringent storage temperature requirements necessary to maintain activity and potency)...
December 20, 2016: Vaccine
https://www.readbyqxmd.com/read/27881489/kinetics-of-meningococcal-serogroup-c-specific-functional-antibody-levels-up-to-15-years-after-a-single-immunization-with-a-meningococcal-serogroup-c-conjugate-vaccine-during-adolescence
#14
Susanne P Stoof, Mariëtte B van Ravenhorst, Debbie M van Rooijen, Richarda M de Voer, Fiona R M van der Klis, Greet J Boland, Elisabeth A M Sanders, Guy A M Berbers, Peter F Teunis
Adolescent vaccination is now considered the key factor for offering direct protection against meningococcal disease but also for reducing carriage and transmission and, in this way, establishing herd protection. This study estimated age-dependent patterns in functional meningococcal serogroup C (MenC) antibody kinetics after primary MenC conjugate (MenCC) vaccination in adolescents. Serum samples (n = 1,676) were drawn from 2006 to 2011 from individuals aged 9 to 18 years at the time of primary MenCC vaccination in 2002...
February 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/27861618/meningococcal-carriage-among-adolescents-after-mass-meningococcal-c-conjugate-vaccination-campaigns-in-salvador-brazil
#15
Amélia Maria Pithon Borges Nunes, Guilherme Sousa Ribeiro, Ítalo Eustáquio Ferreira, Ana Rafaela Silva Simões Moura, Ridalva Dias Martins Felzemburgh, Ana Paula Silva de Lemos, Mitermayer Galvão Reis, José Cassio de Moraes, Leila Carvalho Campos
Neisseria meningitidis is a commensal bacterium of the human nasopharynx. In rare cases, it penetrates the mucosa, entering the blood stream and causing various forms of disease. Meningococcal conjugate vaccines can prevent invasive disease not only by direct effect in vaccinated individuals but also by herd protection, preventing acquisition of carriage, which interrupts transmission and leads to protection of unvaccinated persons. In 2010 in Salvador, Brazil, an outbreak of group C meningococcal disease led to a mass meningococcal serogroup C conjugate vaccination drive, targeting those <5 and 10-24 years of age...
2016: PloS One
https://www.readbyqxmd.com/read/27847367/serum-bactericidal-antibody-responses-of-adults-immunized-with-the-menb-4c-vaccine-against-genetically-diverse-serogroup-b-meningococci
#16
Serena Giuntini, Eduardo Lujan, Malick M Gibani, Christina Dold, Christine S Rollier, Andrew J Pollard, Dan M Granoff
MenB-4C is a meningococcal vaccine for the prevention of serogroup B disease. The vaccine contains factor H binding protein (FHbp) and three other antigens that can elicit serum bactericidal antibodies (SBA). For vaccine licensure, efficacy was inferred from the SBA responses against three antigen-specific indicator strains. The relation between those results and broad protection against circulating genetically diverse strains is not known. Twenty adults were immunized with two doses of MenB-4C given 1 to 2 months apart...
January 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/27846061/neisseria-meningitidis-serogroup-b-vaccine-bivalent-rlp2086-induces-broad-serum-bactericidal-activity-against-diverse-invasive-disease-strains-including-outbreak-strains
#17
Shannon L Harris, Robert G K Donald, Julio Cesar Hawkins, Cuiwen Tan, Robert O'Neill, Lisa K McNeil, John L Perez, Annaliesa S Anderson, Kathrin U Jansen, Thomas R Jones
BACKGROUND: Bivalent rLP2086 (Trumenba®), 1 of 2 meningococcal serogroup B (MnB) vaccines recently approved in the United States for prevention of MnB disease in individuals aged 10-25 years, is composed of 2 lipidated factor H binding proteins (fHBPs) from subfamilies A and B. This study evaluated the breadth of MnB strain coverage elicited by bivalent rLP2086 measured with serum bactericidal assays using human complement (hSBAs). METHODS: hSBA responses to diverse MnB clinical strains circulating in the United States and Europe (n=23), as well as recent US university outbreak strains (n=4), were evaluated...
November 11, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27832151/nationwide-trends-in-bacterial-meningitis-before-the-introduction-of-13-valent-pneumococcal-conjugate-vaccine-burkina-faso-2011-2013
#18
Dinanibè Kambiré, Heidi M Soeters, Rasmata Ouédraogo-Traoré, Isaïe Medah, Lassana Sangare, Issaka Yaméogo, Guetawendé Sawadogo, Abdoul-Salam Ouédraogo, Soumeya Hema-Ouangraoua, Lesley McGee, Velusamy Srinivasan, Flavien Aké, Malika Congo-Ouédraogo, Soufian Sanou, Absatou Ky Ba, Ryan T Novak, Chris Van Beneden
BACKGROUND: Following introduction of Haemophilus influenzae type b vaccine in 2006 and serogroup A meningococcal conjugate vaccine in 2010, Streptococcus pneumoniae (Sp) became the leading cause of bacterial meningitis in Burkina Faso. We describe bacterial meningitis epidemiology, focusing on pneumococcal meningitis, before 13-valent pneumococcal conjugate vaccine (PCV13) introduction in the pediatric routine immunization program in October 2013. METHODS: Nationwide population-based meningitis surveillance collects case-level demographic and clinical information and cerebrospinal fluid (CSF) laboratory results...
2016: PloS One
https://www.readbyqxmd.com/read/27817957/long-term-persistence-of-protective-antibodies-in-dutch-adolescents-following-a-meningococcal-serogroup-c-tetanus-booster-vaccination
#19
Mariëtte B van Ravenhorst, Axel Bonacic Marinovic, Fiona R M van der Klis, Debbie M van Rooijen, Marjan van Maurik, Susanne P Stoof, Elisabeth A M Sanders, Guy A M Berbers
INTRODUCTION: Due to waning immunity, infant vaccination with meningococcal serogroup C conjugated (MenCC) vaccines is insufficient to maintain long-term individual protection. Adolescent booster vaccination is thought to offer direct protection against invasive meningococcal disease (IMD) but also to reduce meningococcal carriage and transmission and in this way establish herd protection in the population. Previously, we studied antibody levels after adolescent MenCC booster vaccination...
December 7, 2016: Vaccine
https://www.readbyqxmd.com/read/27808594/immunogenicity-and-safety-among-laboratory-workers-vaccinated-with-bexsero%C3%A2-vaccine
#20
Eva Hong, Aude Terrade, Muhamed-Kheir Taha
Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose...
November 3, 2016: Human Vaccines & Immunotherapeutics
keyword
keyword
49014
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"